Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Shields, Lisa B E ^a,b   Kadner, Robert ^c   Vitaz, Todd W ^a,b   Spalding, Aaron C ^b,d,e  

^a Norton Neuroscience Institute   (United States)

^b Norton Healthcare   (United States)

^c DXP Imaging   (United States)

^d Norton Cancer Institute   (United States)

^e KOSAIR CHILDREN'S HOSPITAL   (United States)

Author keywords

Bevacizumab; Glioblastoma multiforme; Radiation therapy; Recurrence; Temozolomide

Indexed keywords

BEVACIZUMAB; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CRANIOTOMY; DISEASE FREE SURVIVAL; EDEMA; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; HYPERTENSION; INTENSITY MODULATED RADIATION THERAPY; LUNG EMBOLISM; MALE; METASTASIS; OVERALL SURVIVAL; RADIATION DOSE; SURGICAL INFECTION; TREATMENT FAILURE; TREATMENT WITHDRAWAL; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; MIDDLE AGED; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; TUMOR RECURRENCE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES;

EID: 84876968887     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-101     Document Type: Article

References (25)

1. Grossman SA, Batara JF. Current management of glioblastoma multiforme. Semin Oncol 2004, 31(5):635-644. 10.1053/j.seminoncol.2004.07.005, 15497116.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10):987-996. 10.1056/NEJMoa043330, 15758009.
3. Fraass BA, McShan DL, Diaz RF, Ten Haken RK, Aisen A, Gebarski S, Glazer G, Lichter AS. Integration of magnetic resonance imaging into radiation therapy treatment planning: I. Technical considerations. Int J Radiat Oncol Biol Phys 1987, 13(12):1897-1908. 10.1016/0360-3016(87)90358-0, 3679929.
4. Thornton AF, Hegarty TJ, Ten Haken RK, Yanke BR, LaVigne ML, Fraass BA, McShan DL, Greenberg HS. Three-dimensional treatment planning of astrocytomas: a dosimetric study of cerebral irradiation. Int J Radiat Oncol Biol Phys 1991, 20(6):1309-1315. 10.1016/0360-3016(91)90243-W, 2045305.
5. Chan JL, Lee SW, Fraass BA, Normolle DP, Greenberg HS, Junck LR, Gebarski SS, Sandler HM. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 2002, 20(6):1635-1642. 10.1200/JCO.20.6.1635, 11896114.
6. Fitzek MM, Thornton AF, Rabinov JD, Lev MH, Pardo FS, Munzenrider JE, Okunieff P, Bussiere M, Braun I, Hochberg FH, Hedley-Whyte ET, Liebsch NJ, Harsh GR. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial. J Neurosurg 1999, 91(2):251-260. 10.3171/jns.1999.91.2.0251, 10433313.
7. Garden AS, Maor MH, Yung WK, Bruner JM, Woo SY, Moser RP, Lee YY. Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas. Radiother Oncol 1991, 20(2):99-110. 10.1016/0167-8140(91)90143-5, 1851573.
8. Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1989, 16(6):1405-1409. 10.1016/0360-3016(89)90941-3, 2542195.
9. Chamberlain MC, Raizer J. Antiangiogenic therapy for high-grade gliomas. CNS Neurol Disord Drug Targets 2009, 8(3):184-194. 10.2174/187152709788680706, 19601816.
10. Gilbert MR, Friedman HS, Kuttesch JF, Prados MD, Olson JJ, Reaman GH, Zaknoen SL. A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro Oncol 2002, 4(4):261-267. 1920664, 12356356.
11. Jain RK, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT, di TE Angiogenesis in brain tumours. Nat Rev Neurosci 2007, 8(8):610-622. di TE.
12. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10(5):459-466. 10.1016/S1470-2045(09)70025-7, 19269895.
13. Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D, Isachenko N, Fouse SD, Phillips JJ, Cheresh DA, Park M, Bergers G. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012, 22(1):21-35. 10.1016/j.ccr.2012.05.037, 22789536.
14. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010, 28(11):1963-1972. 10.1200/JCO.2009.26.3541, 20231676.
15. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285(21):1182-1186. 10.1056/NEJM197111182852108, 4938153.
16. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27(28):4733-4740. 10.1200/JCO.2008.19.8721, 19720927.
17. Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham C, Yong WH, Mischel P, Liau LM, Bergsneider M, Pope W, Selch M, Cloughesy T. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 2008, 71(5):1372-1380. 10.1016/j.ijrobp.2007.11.068, 18355978.
18. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, Phuphanich S, Black K, Peak S, Green RM, Spier CE, Kolevska T, Polikoff J, Fehrenbacher L, Elashoff R, Cloughesy T. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011, 29(2):142-148. 10.1200/JCO.2010.30.2729, 3058273, 21135282.
19. Vredenburgh JJ, Desjardins A, Kirkpatrick JP, Reardon DA, Peters KB, Herndon JE, Marcello J, Bailey L, Threatt S, Sampson J, Friedman A, Friedman HS. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2010, In press.
20. Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon JE, Marcello J, Kirkpatrick JP, Sampson JH, Bailey L, Threatt S, Friedman AH, Bigner DD, Friedman HS. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 2011, 17(12):4119-4124. 10.1158/1078-0432.CCR-11-0120, 3117928, 21531816.
21. Narayana A, Gruber D, Kunnakkat S, Golfinos JG, Parker E, Raza S, Zagzag D, Eagan P, Gruber ML. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg 2012, 116(2):341-345. 10.3171/2011.9.JNS11656, 22035272.
22. Lee SW, Fraass BA, Marsh LH, Herbort K, Gebarski SS, Martel MK, Radany EH, Lichter AS, Sandler HM. Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys 1999, 43(1):79-88. 10.1016/S0360-3016(98)00266-1, 9989517.
23. Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, Weinstein A, Nelson JS, Tsukada Y. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 1983, 52(6):997-1007. 10.1002/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO;2-2, 6349785.
24. Hess CF, Schaaf JC, Kortmann RD, Schabet M, Bamberg M. Malignant glioma: patterns of failure following individually tailored limited volume irradiation. Radiother Oncol 1994, 30(2):146-149. 10.1016/0167-8140(94)90044-2, 8184112.
25. Chinot O, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R. Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly-diagnosed glioblastoma: mature progression-free survival and preliminary overall survival results in Avaglio [Abstract]. Neuro Oncol 2012, 14(6):101. 3245999, 22013168.